{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T01:04:17Z","timestamp":1787879057856,"version":"build-2784847793"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40256-021-00464-y","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T04:03:04Z","timestamp":1616731384000},"page":"535-543","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis"],"prefix":"10.1007","volume":"21","author":[{"given":"Camille","family":"Vong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4085-1577","authenticated-orcid":false,"given":"Lutz O.","family":"Harnisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,26]]},"reference":[{"key":"464_CR1","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1474-4422(11)70246-0","volume":"10","author":"V Plant\u00e9-Bordeneuve","year":"2011","unstructured":"Plant\u00e9-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10:1086\u201397.","journal-title":"Lancet Neurol."},{"key":"464_CR2","first-page":"S107","volume":"23","author":"MA Gertz","year":"2017","unstructured":"Gertz MA. Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care. 2017;23:S107\u201312.","journal-title":"Am J Manag Care."},{"key":"464_CR3","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","volume":"126","author":"FL Ruberg","year":"2012","unstructured":"Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126:1286\u2013300.","journal-title":"Circulation"},{"key":"464_CR4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","volume":"133","author":"LH Connors","year":"2016","unstructured":"Connors LH, Sam F, Skinner M, Salinaro F, Sun F, Ruberg FL, et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. Circulation. 2016;133:282\u201390.","journal-title":"Circulation"},{"key":"464_CR5","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73:2872\u201391.","journal-title":"J Am Coll Cardiol."},{"key":"464_CR6","doi-asserted-by":"publisher","first-page":"9629","DOI":"10.1073\/pnas.1121005109","volume":"109","author":"CE Bulawa","year":"2012","unstructured":"Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA. 2012;109:9629\u201334.","journal-title":"Proc Natl Acad Sci USA"},{"key":"464_CR7","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","volume":"79","author":"T Coelho","year":"2012","unstructured":"Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Plant\u00e9-Bordeneuve V, Lozeron P, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79:785\u201392.","journal-title":"Neurology"},{"key":"464_CR8","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","volume":"260","author":"T Coelho","year":"2013","unstructured":"Coelho T, Maia LF, da Silva AM, Cruz MW, Plant\u00e9-Bordeneuve V, Suhr OB, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013;260:2802\u201314.","journal-title":"J Neurol."},{"key":"464_CR9","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1080\/13506129.2017.1357545","volume":"24","author":"FA Barroso","year":"2017","unstructured":"Barroso FA, Judge DP, Ebede B, Li H, Stewart M, Amass L, et al. Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid. 2017;24:194\u2013204.","journal-title":"Amyloid"},{"key":"464_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40120-016-0040-x","volume":"5","author":"T Coelho","year":"2016","unstructured":"Coelho T, Merlini G, Bulawa CE, Fleming JA, Judge DP, Kelly JW, et al. Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis. Neurol Ther. 2016;5:1\u201325.","journal-title":"Neurol Ther."},{"key":"464_CR11","unstructured":"Pfizer Limited. Tafamidis 20 mg Summary of Product Characteristics. 2016. https:\/\/www.medicines.org.uk\/emc\/product\/2837\/smpc. Accessed 12 June 2020."},{"key":"464_CR12","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007\u201316.","journal-title":"N Engl J Med."},{"key":"464_CR13","doi-asserted-by":"publisher","first-page":"e003815","DOI":"10.1161\/CIRCHEARTFAILURE.116.003815","volume":"10","author":"MS Maurer","year":"2017","unstructured":"Maurer MS, Elliott P, Merlini G, Shah SJ, Cruz MW, Flynn A, et al. Design and rationale of the phase 3 ATTR-ACT clinical trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). Circ Heart Fail. 2017;10:e003815.","journal-title":"Circ Heart Fail."},{"key":"464_CR14","unstructured":"Pfizer Inc. VYNDAQEL\u00ae (tafamidis meglumine) prescribing information. US Food and Drug Administration. 2019. https:\/\/www.fda.gov\/media\/126283\/download. Accessed 20 Sept 2019."},{"key":"464_CR15","unstructured":"Pfizer Inc. Vyndaqel (tafamidis) 20 mg and 61 mg summary of product characteristics. European Medicines Agency. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vyndaqel-epar-product-information_en.pdf. Accessed 12 June 2020."},{"key":"464_CR16","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1002\/(SICI)1097-0258(19990615)18:11<1341::AID-SIM129>3.0.CO;2-7","volume":"18","author":"DM Finkelstein","year":"1999","unstructured":"Finkelstein DM, Schoenfeld DA. Combining mortality and longitudinal measures in clinical trials. Stat Med. 1999;18:1341\u201354.","journal-title":"Stat Med."},{"key":"464_CR17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1023\/A:1020930626404","volume":"27","author":"EH Cox","year":"1999","unstructured":"Cox EH, Veyrat-Follet C, Beal SL, Fuseau E, Kenkare S, Sheiner LB. A population pharmacokinetic\u2013pharmacodynamic analysis of repeated measures time-to-event pharmacodynamic responses: the antiemetic effect of ondansetron. J Pharmacokinet Biopharm. 1999;27:625\u201344.","journal-title":"J Pharmacokinet Biopharm."},{"key":"464_CR18","unstructured":"Hooker AC, Karlsson MO. The Kaplan-Meier mean covariate plot (KMCC): a new diagnostic for covariates in time-to-event models. In: Annual Meeting of the Population Approach Group in Europe (PAGE); 2012; Venice, Italy."},{"key":"464_CR19","doi-asserted-by":"publisher","first-page":"752","DOI":"10.4070\/kcj.2013.43.11.752","volume":"43","author":"MH Lee","year":"2013","unstructured":"Lee MH, Lee SP, Kim YJ, Sohn DW. Incidence, diagnosis and prognosis of cardiac amyloidosis. Korean Circ J. 2013;43:752\u201360.","journal-title":"Korean Circ J."},{"key":"464_CR20","first-page":"709","volume":"7","author":"RM Witteles","year":"2019","unstructured":"Witteles RM, Bokhari S, Damy T, Elliott PM, Falk RH, Fine NM, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. J Am Coll Cardiol Heart Fail. 2019;7:709\u201316.","journal-title":"J Am Coll Cardiol Heart Fail."},{"key":"464_CR21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","volume":"68","author":"MS Maurer","year":"2016","unstructured":"Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68:161\u201372.","journal-title":"J Am Coll Cardiol."},{"key":"464_CR22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12872-018-0952-8","volume":"18","author":"P Kyriakou","year":"2018","unstructured":"Kyriakou P, Mouselimis D, Tsarouchas A, Rigopoulos A, Bakogiannis C, Noutsias M, et al. Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers. BMC Cardiovasc Disord. 2018;18:221.","journal-title":"BMC Cardiovasc Disord."},{"key":"464_CR23","doi-asserted-by":"publisher","first-page":"e0173086","DOI":"10.1371\/journal.pone.0173086","volume":"12","author":"AV Kristen","year":"2017","unstructured":"Kristen AV, Maurer MS, Rapezzi C, Mundayat R, Suhr OB, Damy T. Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis\u2014Report from the Transthyretin Amyloidosis Outcome Survey (THAOS). PLoS ONE. 2017;12:e0173086.","journal-title":"PLoS ONE"},{"key":"464_CR24","doi-asserted-by":"crossref","unstructured":"Damy T, Garcia-Pavia P, Hanna M, Judge DP, Merlini G, Gundapaneni B, et al. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail. 2020.","DOI":"10.1002\/ejhf.2027"},{"key":"464_CR25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3949\/ccjm.84.s3.02","volume":"84","author":"JP Donnelly","year":"2017","unstructured":"Donnelly JP, Hanna M. Cardiac amyloidosis: an update on diagnosis and treatment. Cleve Clin J Med. 2017;84:12\u201326.","journal-title":"Cleve Clin J Med."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-021-00464-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-021-00464-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-021-00464-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T11:28:04Z","timestamp":1631532484000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-021-00464-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,26]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["464"],"URL":"https:\/\/doi.org\/10.1007\/s40256-021-00464-y","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,26]]},"assertion":[{"value":"19 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This analysis was sponsored by Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"S. Riley, M. Boucher, and L.O. Harnisch are full-time employees of, and hold stock and\/or stock options with, Pfizer. C. Vong was a full-time employee of Pfizer at the time of the analysis; she is now a full-time employee of Novartis AG and holds stock options with Novartis AG.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"ATTR-ACT was approved by the independent review board or ethics committee at each participating site and was conducted in accordance with the provisions of the Declaration of Helsinki and the International Council for Harmonisation Good Clinical Practice guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors have given their consent for the publication of this manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual anonymized participant data. See\n                      \n                      for more information.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the design of the analysis, data acquisition and interpretation, and to the drafting and revising of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}